Innovative Bladder Cancer Therapy Reprograms Bone Marrow to Enhance Immune Response
New research uncovers how bladder cancer treatment with BCG reprograms the bone marrow to enhance the body's innate immune response, improving cancer-fighting capabilities.
A groundbreaking study by researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) reveals that bladder cancer treatment with Bacillus Calmette-Guérin (BCG) not only stimulates a local immune response but also induces systemic immunological changes by reprogramming the bone marrow. BCG, a weakened form of Mycobacterium bovis, has long been used as a frontline immunotherapy for early-stage bladder cancer. Traditionally thought to act mainly at the tumor site by enhancing T cell activity, new evidence suggests that BCG's effects extend deeper into the body's immune system.
The research demonstrates that BCG travels from the bladder to the bone marrow, influencing the production of immune cells called myeloid cells. This process primes the innate immune system, enabling it to respond more effectively to cancer cells and other threats. Using advanced analytical techniques like Progenitor Input Enrichment sequencing (PIE-seq), scientists studied gene activity in blood samples from bladder cancer patients treated with BCG, discovering significant changes in stem cell programming in the bone marrow.
Notably, the study shows that the reprogrammed stem cells generate more potent immune cells capable of attacking tumors. Additionally, combining BCG with checkpoint inhibitors—a type of immunotherapy that boosts T cell activity—resulted in more effective tumor suppression and increased survival in mouse models. This synergy indicates potential for enhancing current cancer treatments by harnessing innate immunity.
The findings broaden the understanding of BCG's anti-cancer mechanisms, highlighting its capacity to shape systemic immune responses beyond the bladder. The research also opens pathways for developing strategies that stimulate immune cell reprogramming to improve immunotherapy outcomes across various cancer types.
This work underscores the importance of innate immune system training in cancer therapy and suggests that leveraging bone marrow reprogramming could augment existing immunotherapies, paving the way for more effective treatment protocols.
Source: https://medicalxpress.com/news/2025-05-bladder-cancer-treatment-reprograms-bone.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Understanding Logical Thinking in Humans and Animals: Challenges and Insights
Exploring how humans and animals think logically reveals complex cognitive processes. New research highlights the distinctions between different types of reasoning and their implications for science and medicine.
Machine Learning Reveals Social Risk Clusters Linked to Suicide Across the United States
A new study using machine learning identifies social and economic risk profiles linked to higher suicide rates in different U.S. regions, paving the way for targeted prevention strategies.
Microbiota's Future Role in Diagnostics and Therapy: Insights from Experts
Experts predict that microbiota-based diagnostics and therapies will become a cornerstone of personalized medicine within the next decade, transforming clinical practice through biomarker development and innovative treatments.
Liquid Biopsy-Driven Treatment Switch Enhances Outcomes in Breast Cancer Recurrence
A groundbreaking clinical trial shows that early detection of resistance mutations via liquid biopsy and switching to experimental drugs can significantly improve outcomes for advanced breast cancer patients.